Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Short term Debt: 2017-2021

Historic Short term Debt for Cidara Therapeutics (CDTX) over the last 5 years, with Dec 2021 value amounting to $2.6 million.

  • Cidara Therapeutics' Short term Debt fell 92.30% to $370,000 in Q2 2022 from the same period last year, while for Jun 2022 it was $370,000, marking a year-over-year decrease of 92.30%. This contributed to the annual value of $2.6 million for FY2021, which is 63.11% down from last year.
  • Cidara Therapeutics' Short term Debt amounted to $2.6 million in FY2021, which was down 63.11% from $7.0 million recorded in FY2020.
  • Cidara Therapeutics' Short term Debt's 5-year high stood at $10.0 million during FY2019, with a 5-year trough of $2.6 million in FY2021.
  • Its 3-year average for Short term Debt is $6.5 million, with a median of $7.0 million in 2020.
  • In the last 5 years, Cidara Therapeutics' Short term Debt spiked by 272.25% in 2018 and then plummeted by 63.11% in 2021.
  • Yearly analysis of 5 years shows Cidara Therapeutics' Short term Debt stood at $2.7 million in 2017, then surged by 272.25% to $9.9 million in 2018, then increased by 0.37% to $10.0 million in 2019, then fell by 29.52% to $7.0 million in 2020, then crashed by 63.11% to $2.6 million in 2021.